XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets

Fundamentals of Solid Formulation | Weekly Webinar Series

April 7, 14, 21, 28, May 5, 12, 19 | 11:00 AM – Noon EDT

Building an AI-powered Drug R&D Engine

to empower pharmaceutical research with increased efficiency and success rate.

AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment

Led by SoftBank Vision Fund, PICC Capital, and Morningside

How Quantum Physics and AI is Disrupting Drug Discovery & Development

Case study on how XtalPi is helping Pfizer scientists predict and optimize the crystalline forms of drug candidates.

XtalPi and PhoreMost Sign Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets

Fundamentals of Solid Formulation | Weekly Webinar Series

April 7, 14, 21, 28, May 5, 12, 19 | 11:00 AM – Noon EDT

Drug Solid-State R&D

For solid-state R&D of small molecule drugs, the XtalPi solution integrates several state-of-the-art technologies for crystal structure prediction, crystal structure determination, virtual screening of salts and cocrystals, as well as an advanced solid-state R&D experimental platform. The company is dedicated to creating the next-generation platform for solid-state R&D for small molecules by combining experimental screening and characterization with theoretical calculations and analyses, and providing novel solutions for the solid-state R&D. At XtalPi, we help our clients improve the quality and efficiency of solid-state R&D and reduce R&D risks and costs.

Crystal Structure Prediction

XtalPi offers accurate prediction of the relative thermodynamic stabilities of different crystal structures through large-scale virtual crystal structure generation and high-precision energy calculation.

Solid-State Screening and Evaluation

XtalPi performs experimental solid-state screening, crystallization process scale-up, and systematic characterization of crystal forms with desired properties, making recommendations to customers based on systematic assessments.

Crystal Structure Determination

XtalPi's solid-state research and development platform combines experimental data and theoretical analyses to determine the crystal structures of solid forms reliably.

Solid-State Testing and Analysis

XtalPi uses a wide range of experimental techniques for the characterization of pharmaceutical solid forms, such as XRD, TGA, DSC, DVS, and HSM.

Crystallization Process Development

With its strong chemical engineering expertise, XtalPi provides professional crystallization process development services to help clients effectively improve solid drug production efficiency.

banner
FUNDAMENTALS OF SOLID FORMULATION
Finished
June 16, 2020-July 29, 2020
online
2019 RSFD Rational Solid Form…2019-10
RSFD Pre-summit Workshop2019-10
...
AI-biotech XtalPi Partners with Singleron to Discover Novel Targeted Therapies for GI Cancers

XtalPi and Singleron will simultaneously conduct target validation and drug discovery, pursuing multiple promising targets and research paths in parallel to boost the efficiency and success rate of novel targeted therapy R&D while lowering their costs.

...
AI Drug R&D Startup XtalPi Announces Over 300 Million Series C Investment Led by SoftBank Vision Fund, PICC Capital, and Morningside

Led by SoftBank Vision Fund, PICC Capital, and Morningside

...
XtalPi and PhoreMost Sign AI-based Pharmaceutical Drug Discovery Collaboration Agreement

Using XtalPi's ID4 platform, the companies will discover drug candidates for "undruggable" targets